Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Imm-6-415
Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Advanced Solid Tumor (Phase 1), Malignant Melanoma (Cutaneous)
Phase I/II
Completed
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Jan 05, 2024
―
Imm-1-104 Monotherapy (Treatment Group A), Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel (Treatment Group B), Imm-1-104 + Modified Folfirinox (Treatment Group C), Imm-1-104 + Dabrafenib (Treatment Group D), Imm-1-104 + Pembrolizumab (Treatment Group E)
Advanced Solid Tumor, Non-Small Cell Lung Cancer (Nsclc), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)
Phase I/II
Active Not Recruiting
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Oct 14, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immuneering (IMRX) have in its pipeline
IMRX is currently developing the following drugs: Imm-6-415, Imm-1-104 Monotherapy (Treatment Group A), Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel (Treatment Group B), Imm-1-104 + Modified Folfirinox (Treatment Group C), Imm-1-104 + Dabrafenib (Treatment Group D), Imm-1-104 + Pembrolizumab (Treatment Group E). These drug candidates are in various stages of clinical development as the company works toward FDA approval.